Dear Yaying Pan

Tumor antigen specific T-cell assays may not be entirely effective in predicting patient response to cancer immunotherapy. Considering the complexity of the immune system, a combination of different assays and making use of dynamic biomarkers will help improve treatment.

Measuring the immunological activity of patients by monitoring changes in T-cell differentiation and tumor antigen profiles, and using combination of assays, for instance the measurement of PD-L1 expression and T cell activation, will provide a more comprehensive picture of the immune response rather than just working on the presence of antigen-specific T cells. The more the information available on the immune response, the better will be the treatment monitoring.

Regards,

Malcolm Nobre